These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

170 related articles for article (PubMed ID: 10348414)

  • 1. Bayesian estimation of cost-effectiveness ratios from clinical trials.
    Heitjan DF; Moskowitz AJ; Whang W
    Health Econ; 1999 May; 8(3):191-201. PubMed ID: 10348414
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Sample size and power issues in estimating incremental cost-effectiveness ratios from clinical trials data.
    Willan AR; O'Brien BJ
    Health Econ; 1999 May; 8(3):203-11. PubMed ID: 10348415
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Bayesian estimation of cost-effectiveness from censored data.
    Heitjan DF; Kim CY; Li H
    Stat Med; 2004 Apr; 23(8):1297-309. PubMed ID: 15083484
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A Bayesian approach to stochastic cost-effectiveness analysis.
    Briggs AH
    Health Econ; 1999 May; 8(3):257-61. PubMed ID: 10348420
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Fieller's method and net health benefits.
    Heitjan DF
    Health Econ; 2000 Jun; 9(4):327-35. PubMed ID: 10862076
    [TBL] [Abstract][Full Text] [Related]  

  • 6. At what price significance? The effect of price estimates on statistical inference in economic evaluation.
    Rittenhouse BE; Dulisse B; Stinnett AA
    Health Econ; 1999 May; 8(3):213-9. PubMed ID: 10348416
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pulling cost-effectiveness analysis up by its bootstraps: a non-parametric approach to confidence interval estimation.
    Briggs AH; Wonderling DE; Mooney CZ
    Health Econ; 1997; 6(4):327-40. PubMed ID: 9285227
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Assessing and comparing costs: how robust are the bootstrap and methods based on asymptotic normality?
    O'Hagan A; Stevens JW
    Health Econ; 2003 Jan; 12(1):33-49. PubMed ID: 12483759
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A Bayesian model averaging approach for cost-effectiveness analyses.
    Conigliani C; Tancredi A
    Health Econ; 2009 Jul; 18(7):807-21. PubMed ID: 18792078
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Trying to do better than average: a commentary on 'statistical inference for cost-effectiveness ratios'.
    Briggs A; Fenn P
    Health Econ; 1997; 6(5):491-5. PubMed ID: 9353649
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Bayesian estimation of cost-effectiveness: an importance-sampling approach.
    Heitjan DF; Li H
    Health Econ; 2004 Feb; 13(2):191-8. PubMed ID: 14737756
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Bayesian methods for design and analysis of cost-effectiveness trials in the evaluation of health care technologies.
    O'Hagan A; Stevens JW
    Stat Methods Med Res; 2002 Dec; 11(6):469-90. PubMed ID: 12516985
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A Bayesian approach to stochastic cost-effectiveness analysis. An illustration and application to blood pressure control in type 2 diabetes.
    Briggs AH
    Int J Technol Assess Health Care; 2001; 17(1):69-82. PubMed ID: 11329846
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Analysis of uncertainty in health care cost-effectiveness studies: an introduction to statistical issues and methods.
    O'Brien BJ; Briggs AH
    Stat Methods Med Res; 2002 Dec; 11(6):455-68. PubMed ID: 12516984
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Confidence intervals for cost-effectiveness ratios: a comparison of four methods.
    Polsky D; Glick HA; Willke R; Schulman K
    Health Econ; 1997; 6(3):243-52. PubMed ID: 9226142
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A systematic review and economic evaluation of the clinical effectiveness and cost-effectiveness of aldosterone antagonists for postmyocardial infarction heart failure.
    McKenna C; Burch J; Suekarran S; Walker S; Bakhai A; Witte K; Harden M; Wright K; Woolacott N; Lorgelly P; Fenwick L; Palmer S
    Health Technol Assess; 2010 May; 14(24):1-162. PubMed ID: 20492762
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Using covariates to reduce uncertainty in the economic evaluation of clinical trial data.
    Vázquez-Polo FJ; Negrín Hernández MA; López-Valcárcel BG
    Health Econ; 2005 Jun; 14(6):545-57. PubMed ID: 15497202
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Methods for economic evaluation alongside a multicentre trial in developing countries: a case study from the WHO Antenatal Care Randomised Controlled Trial.
    Mugford M; Hutton G; Fox-Rushby J
    Paediatr Perinat Epidemiol; 1998 Oct; 12 Suppl 2():75-97. PubMed ID: 9805724
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A Bayesian approach to economic analyses of clinical trials: the case of stenting versus balloon angioplasty.
    Al MJ; Van Hout BA
    Health Econ; 2000 Oct; 9(7):599-609. PubMed ID: 11103926
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Confidence intervals for cost/effectiveness ratios.
    Wakker P; Klaassen MP
    Health Econ; 1995; 4(5):373-81. PubMed ID: 8563835
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.